Who
Ashwath Jayagopal
Chief Scientific & Dev. Ofc.
Company insider
Files Form 4 as: Chief Scientific & Dev. Ofc., Opus Genetics.
In numbers
- Trades disclosed
- 14
- Buys
- 1
- Sells
- 2
- Bought
- $6,195
- Sold
- $116K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 12 Feb 2024
- Last trade
- 23 Apr 2026
- Last filed
- 27 Apr 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 23 Apr 2026filed 27 Apr 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Sold | $39K7,542 at $5.19 | filing |
| 23 Apr 2026filed 27 Apr 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Sold | $39K7,542 at $5.19 | filing |
| 16 Mar 2026filed 18 Mar 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Sold | $19K3,719 at $5.12 | filing |
| 16 Mar 2026filed 18 Mar 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Sold | $19K3,719 at $5.12 | filing |
| 12 Feb 2026filed 17 Feb 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code F | $18K5,313 at $3.39 | filing |
| 12 Feb 2026filed 17 Feb 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code F | $18K5,313 at $3.39 | filing |
| 22 Jan 2026filed 26 Jan 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code A | —400,000 at $0.00 | filing |
| 22 Jan 2026filed 26 Jan 2026 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code A | —400,000 at $0.00 | filing |
| 13 Mar 2025filed 17 Mar 2025 | IRD Opus Geneticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —52,500 at $0.00 | filing |
| 13 Mar 2025filed 17 Mar 2025 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code A | —52,500 at $0.00 | filing |
| 13 Feb 2025filed 18 Feb 2025 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code F | $5,9725,193 at $1.15 | filing |
| 22 May 2024filed 24 May 2024 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Bought | $6,1953,500 at $1.77 | filing |
| 12 Feb 2024filed 14 Feb 2024 | IRD Opus Geneticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —225,000 at $0.00 | filing |
| 12 Feb 2024filed 14 Feb 2024 | IRD Opus GeneticsBiotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
News
Opus Genetics Announces FDA Clearance of IND Application for OPGx-RDH12 Gene Therapy for Inherited Childhood BlindnessIRD · manilatimes.net · 21 Oct 2026Opus Genetics Announces FDA Approval of Phentolamine Ophthalmic Solution 0.75% for the Treatment of PresbyopiaIRD · manilatimes.net · 16 Oct 2026Opus Genetics Presents Positive Clinical Data from OPGx-BEST1 and OPGx-LCA5 Gene Therapy Programs at Retina in Rio 2026IRD · manilatimes.net · 15 Oct 2026
0 headlines in the last 90 days name Ashwath Jayagopal; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.